SC
VNDA icon

Savant Capital’s Vanda Pharmaceuticals VNDA Stock Holding History

Savant Capital’s Portfolio VNDA Stock Details VNDA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-15,094
Closed -$72.3K – 1427
2024
Q4 		$72.3K Sell
15,094
-204
-1% -$979 ﹤0.01% 1396
2024
Q3 		$71.7K Sell
15,298
-1,561
-9% -$8.37K ﹤0.01% 1356
2024
Q2 		$95.3K Buy
16,859
+1,765
+12% +$9.12K ﹤0.01% 1208
2024
Q1 		$62K Buy
+15,094
New +$60.4K ﹤0.01% 1094

Other funds holding VNDA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $43.4B AUM 51.29% 1-Year Est. Return

Savant Capital's VNDA Position: Q1 2025 in Review

Savant Capital sold out of Vanda Pharmaceuticals (VNDA) in Q1 2025, closing a stake of 15,094 shares — an estimated $72.3K sold.

Savant Capital first reported a position in VNDA in Q1 2024 and held it in 4 quarters. The position peaked at $95.3K in Q2 2024. 146 funds tracked by Wall St. Rank hold VNDA as of Q1 2025.

  • Savant Capital reported no remaining Vanda Pharmaceuticals position as of Q1 2025 after selling out during the quarter.
  • Savant Capital sold 15,094 Vanda Pharmaceuticals shares in Q1 2025, an estimated $72.3K.
  • Savant Capital first reported a position in Vanda Pharmaceuticals in Q1 2024 and held it in 4 quarters.
  • Savant Capital's Vanda Pharmaceuticals position peaked at $95.3K in Q2 2024.
  • 146 funds tracked by Wall St. Rank held Vanda Pharmaceuticals as of Q1 2025.

Based on Savant Capital's 13F filing for Q1 2025, filed 8 May 2025.